---
document_datetime: 2023-09-21 21:10:16
document_pages: 35
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/sitagliptin-accord-epar-public-assessment-report_en.pdf
document_name: sitagliptin-accord-epar-public-assessment-report_en.pdf
version: success
processing_time: 15.7475235
conversion_datetime: 2025-12-27 15:48:07.591174
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 February 2022 EMA/181231/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Sitagliptin Accord

International non-proprietary name: sitagliptin

Procedure No. EMEA/H/C/005598/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................6                        |                                                                                        |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier.............................................................................      | 6                                                                                      |
| 1.2. Legal basis, dossier content..........................................................................      | 6                                                                                      |
| 1.3. Information on paediatric requirements............................................................          | 7                                                                                      |
| 1.4. Information relating to orphan market exclusivity...............................................            | 7                                                                                      |
| 1.4.1. Similarity............................................................................................... | 7                                                                                      |
| 1.5. Scientific advice.........................................................................................  | 8                                                                                      |
| 1.6. Steps taken for the assessment of the product...................................................            | 8                                                                                      |
| 2. Scientific discussion..............................................................................10         |                                                                                        |
| 2.1. Introduction.............................................................................................10 |                                                                                        |
| 2.2. Quality aspects.........................................................................................11  |                                                                                        |
| 2.2.1. Introduction..........................................................................................11  |                                                                                        |
| 2.2.2. Active substance                                                                                          | ....................................................................................11 |
| 2.2.3. Finished medicinal product........................................................................14      |                                                                                        |
| 2.2.4. Discussion on chemical, and pharmaceutical aspects........................................17              |                                                                                        |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects.....................17                 |                                                                                        |
| 2.2.6. Recommendation(s) for future quality development.........................................17               |                                                                                        |
| 2.3. Non-clinical aspects...................................................................................18   |                                                                                        |
| 2.3.1. Introduction..........................................................................................18  |                                                                                        |
| 2.3.2. Ecotoxicity/environmental risk assessment....................................................18           |                                                                                        |
| 2.3.3. Discussion on non-clinical aspects...............................................................18       |                                                                                        |
| 2.3.4. Conclusion on the non-clinical aspects..........................................................18        |                                                                                        |
| 2.4. Clinical aspects.........................................................................................19 |                                                                                        |
| 2.4.1. Introduction..........................................................................................19  |                                                                                        |
| 2.4.2. Clinical pharmacology..............................................................................21     |                                                                                        |
| 2.4.3. Discussion on clinical aspects.....................................................................30     |                                                                                        |
| 2.4.4. Conclusions on clinical aspects...................................................................31      |                                                                                        |
| 2.5. Risk Management Plan................................................................................31      |                                                                                        |
| 2.5.1. Safety concerns......................................................................................31   |                                                                                        |
| 2.5.2. Pharmacovigilance plan............................................................................31      |                                                                                        |
| 2.5.3. Risk minimisation measures                                                                                | ......................................................................32               |
| 2.5.4. Conclusion............................................................................................32  |                                                                                        |
| 2.6. Pharmacovigilance.....................................................................................32    |                                                                                        |
| 2.6.1. Pharmacovigilance system                                                                                  | ........................................................................32             |
| 2.6.2. Periodic Safety Update Reports submission requirements..................................32                |                                                                                        |
| 2.7. Product information...................................................................................32    |                                                                                        |
| 2.7.1. User consultation....................................................................................32   |                                                                                        |
| 3. Benefit-risk balance..............................................................................32          |                                                                                        |
| 4. Recommendations.................................................................................33            |                                                                                        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AAS     | Atomic Absorption Spectrometry                                                                          |
|---------|---------------------------------------------------------------------------------------------------------|
| AP      | Applicant's Part (or Open Part) of an ASMF                                                              |
| RP      | Restricted Part (or Closed Part) of an ASMF                                                             |
| API     | Active Pharmaceutical Ingredient                                                                        |
| ASM     | Active Substance Manufacturer                                                                           |
| ASMF    | Active Substance Master File                                                                            |
| CEP     | Certificate of Suitability of the EP                                                                    |
| CFU     | Colony Forming Units                                                                                    |
| CHMP    | the Committee for Medicinal Products for Human Use                                                      |
| CMS     | Concerned Member State                                                                                  |
| CoA     | Certificate of Analysis                                                                                 |
| CQA     | Critical Quality Attribute                                                                              |
| CRS     | Chemical Reference Substance (official standard)                                                        |
| DS      | Drug Substance                                                                                          |
| DSM     | Drug Substance Manufacturer                                                                             |
| DP      | Drug Product                                                                                            |
| DPM     | Drug Product Manufacturer                                                                               |
| DSC     | Differential Scanning Calorimetry                                                                       |
| EDQM    | European Directorate for the Quality of Medicines                                                       |
| EMA     | European Medicines Agency                                                                               |
| EPAR    | European Public Assessment Report                                                                       |
| ERA     | Environmental Risk Assessment                                                                           |
| F pen : | Market penetration factor                                                                               |
| GCP     | Good Clinical Practice                                                                                  |
| GLP     | Good Laboratory Practice                                                                                |
| GMP     | Good Manufacturing Practice                                                                             |
| HDPE    | High Density Polyethylene                                                                               |
| HPLC    | High Performance Liquid Chromatography                                                                  |
| ICH     | the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use |
| ICP     | Inductively Coupled Plasma                                                                              |
| IPC     | In-Process Control                                                                                      |

<div style=\"page-break-after: always\"></div>

| IR      | Infrared (spectroscopy)                                |
|---------|--------------------------------------------------------|
| IU      | International Units                                    |
| LDPE    | Low Density Polyethylene                               |
| LOA     | Letter of Access                                       |
| LOD     | Limit of Detection                                     |
| Log Kow | n-octanol/water partition coefficient                  |
| LoQ     | List of Questions                                      |
| LT      | Less Than                                              |
| MAH     | Marketing Authorisation Holder                         |
| MS      | Mass Spectrometry                                      |
| ND      | Not Detected                                           |
| NLT     | Not Less Than                                          |
| NMR     | Nuclear Magnetic Resonance                             |
| NMT     | Not More Than                                          |
| NOEC    | No Effect Concentration                                |
| OECD    | Organization for Economic Co-Operation and Development |
| OES     | Optical Emission Spectrometry                          |
| OOS     | Out of Specification                                   |
| PDE     | Permitted Daily Exposure                               |
| PE      | Polyethylene                                           |
| PEC     | Predicted Environmental Concentration                  |
| PNEC    | Predicted No Effect Concentrations                     |
| Ph.Eur. | European Pharmacopoeia                                 |
| PIL     | Patient Information Leaflet                            |
| PP      | Polypropylene                                          |
| PSD     | Particle Size Distribution                             |
| PVC     | Polyvinylchloride                                      |
| PVDC    | Polyvinylidene chloride                                |
| XR(P)D  | X-Ray (Powder) Diffraction                             |
| QP      | Qualified Person                                       |
| RH      | Relative Humidity                                      |
| RMS     | Reference Member State                                 |
| (R)RT   | (Relative) Retention time                              |

<div style=\"page-break-after: always\"></div>

RSD Relative Standard Deviation SM Starting Material S(m)PC Summary of Product Characteristics TGA Thermo-Gravimetric Analysis UV Ultraviolet (spectroscopy) USP U.S. Pharmacopeia * This is a general list of abbreviations. Not all abbreviations will be used

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Accord Healthcare S.L.U. submitted on 4 May 2020 an application for marketing authorisation to the European Medicines Agency (EMA) for Sitagliptin Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004- 'Generic of a Centrally authorised product'. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 March 2020.

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product, as defined in Article 10 (2)(a) of Directive 2001/83/EC, for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indication:

For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control:

as monotherapy:

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with:

- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
- a peroxisome proliferator-activated receptor gamma (PPAR γ ) agonist (i.e. a thiazolidinedione) when use of a PPAR γ agonist is appropriate and when diet and exercise plus the PPAR γ agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with:

- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
- a PPAR γ agonist and metformin when use of a PPAR γ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information, complete quality data, a

<div style=\"page-break-after: always\"></div>

bioequivalence study with the reference medicinal product Januvia and appropriate non-clinical and clinical data.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with Union provisions in force for not less than 10 years in the EEA:

- Product name, strength, pharmaceutical form: Januvia, 25 mg, 50 mg and 100mg, film-coated tablet
- Marketing authorisation holder: Merck Sharp &amp; Dohme B.V.
- Date of authorisation: 21-03-2007
- Marketing authorisation granted by:
- -Union
- Union Marketing authorisation number: EU/1/07/383

Medicinal product authorised in the Union/Members State where the application is made or European reference medicinal product:

- Product name, strength, pharmaceutical form: Januvia, 25 mg, 50 mg and 100mg, film-coated tablet
- Marketing authorisation holder: Merck Sharp &amp; Dohme B.V.
- Date of authorisation: 21-03-2007
- Marketing authorisation granted by:
- -Union
- Marketing authorisation number: EU/1/07/383

Medicinal product which is or has been authorised in accordance with Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

- Product name, strength, pharmaceutical form: Januvia, 100 mg, film-coated tablet
- Marketing authorisation holder: Merck Sharp &amp; Dohme B.V.
- Date of authorisation: 21-03-2007
- Marketing authorisation granted by:
- -Union
- -Marketing authorisation number(s): EU/1/07/383
- Bioavailability study number(s): PCLPL-027-19 &amp; 62020

## 1.3. Information on paediatric requirements

Not applicable.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.5. Scientific advice

The applicant did not seek Scientific advice from the CHMP.

## 1.6. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was: Simona Badoi

| The application was received by the EMA on                                                                                                                                      | 04 May 2020       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                                        | 21 May 2020       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                    | 11 August 2020    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                    | 13 August 2020    |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                         | 17 September 2020 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                             | 18 March 2021     |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP and PRAC members on      | 26 April 2021     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                        | 6 May 2021        |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Updated Joint Assessment Report to all CHMP and PRAC members on                                                    | 12 May 2021       |
| The CHMP agreed on a List of outstanding issues in writing and/or Oral Explanation to be sent to the applicant on                                                               | 21 May 2021       |
| The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on                                                                                    | 17 August 2021    |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on         | 31 August 2021    |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Updated Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on | 8 September 2021  |
| The CHMP agreed on 2 nd List of outstanding issues in writing and/or Oral Explanation to be sent to the applicant on                                                            | 16 September 2021 |
| The applicant submitted the responses to the CHMP consolidated 2 nd List of Outstanding Issues on                                                                               | 15 November 2021  |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint                                                                                                              | 1 December 2021   |

<div style=\"page-break-after: always\"></div>

| Assessment Report on the responses to the 2 nd List of Outstanding Issues to all CHMP and PRAC members on                                                                                          |                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Updated Assessment Report on the responses to the 2 nd List of Outstanding Issues to all CHMP and PRAC members on               | 9 December 2021  |
| The CHMP agreed on 3 rd List of outstanding issues in writing and/or Oral Explanation o be sent to the applicant on                                                                                | 17 December 2021 |
| The applicant submitted the responses to the CHMP consolidated 3 rd List of Outstanding Issues on                                                                                                  | 21 January 2022  |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the 3 rd List of Outstanding Issues to all CHMP and PRAC members on                       | 9 February 2022  |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Updated Assessment Report on the responses to the 3 rd List of Outstanding Issues to all CHMP and PRAC members on               | 15 February 2022 |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                            | N/A              |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Sitagliptin Accord on | 24 February 2022 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

The application for marketing authorisation of Sitagliptin Accord 25 mg, 50 mg and 100 mg film-coated tablets is a generic application of a centrally authorised medicinal product according to Art. 10(1) of Directive 2001/83/EC, as amended. In this assessment report, the name Sitagliptin Accord is used. The reference product is Januvia 25 mg, 50 mg and 100 mg film-coated tablets marketed by Merck Sharp &amp; Dohme B.V., the Netherlands, was first authorised in the European Union on 21 March 2007 via the centralised procedure (EU/1/07/383).

The active substance sitagliptin is an oral blood glucose-lowering drug used in the treatment of type 2 diabetes mellitus. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by elevated levels of blood glucose, which prevalence has been increasing steadily all over the world. Type 2 diabetes mellitus is due primarily to lifestyle factors and genetics. Type 2 diabetes mellitus is characterized by insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual pancreatic beta-cell failure. In type 2 diabetes mellitus, the body does not produce enough insulin or the cells ignore the insulin. Over time, high blood sugar levels can increase the risk for serious complications, including serious damage to the heart, blood vessels, eyes, kidneys and nerves.

Sitagliptin is an active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4 inhibitor) that has been approved for the therapy of type 2 diabetes. Sitagliptin 100 mg daily was well tolerated and provided effective and sustained improvement in HbA1c, FPG and PPG levels. Sitagliptin prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Sitagliptin metabolizes the naturally occurring incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) resulting in enhanced glucosedependent insulin secretion from the pancreas and decreased hepatic glucose production.

## Therapeutic indication

For adult patients with type 2 diabetes mellitus, sitagliptin is indicated to improve glycaemic control:

as monotherapy:

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with:

- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.

- a peroxisome proliferatoractivated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with:

- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

<div style=\"page-break-after: always\"></div>

- -a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as a film-coated tablet containing 25 mg, 50 mg or 100 mg of Sitagliptin (as hydrochloride monohydrate) as active substance.

Other ingredients are:

Tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate, croscarmellose sodium (E468), magnesium stearate (E470b);

Film-coating:  polyvinyl alcohol, titanium dioxide, macrogol 3350, talc (E553b), iron oxide yellow (E172) and iron oxide red (E172).

The finished product is packaged in PVC/PE/PVDC - Alu blisters as described in section 6.5 of the SmPC.

## 2.2.2. Active substance

## 2.2.2.1. General Information

The documentation on the active substance is presented using an Active Substance Master File (ASMF) procedure.

The chemical name of sitagliptin hydrochloride monohydrate is (3 R )-3-amino-1-[3-(trifluoromethyl)5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8 H )-yl]-4-(2,4,5-trifluorophenyl)butan-1-one  hydrochloride monohydrate or (2 R )-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8 H )-yl]1-(2,4,5-trifluoro phenyl)butan-2-amine hydrochloride monohydrate, corresponding to the molecular formula C16H18ClF6N5O2. It has a relative molecular mass of 461.8 and the following structure:

Figure 1: active substance structure

<!-- image -->

The chemical structure of sitagliptin hydrochloride monohydrate was elucidated by a combination of Elemental Analysis, High Resolution Mass Spectrometry, Nuclear Magnetic Resonance Spectroscopy ( 1 H &amp;  13 C NMR), Infrared Spectroscopy, and UV Spectroscopy.

The solid-state properties of the active substance were measured by X-Ray powder diffraction.

Sitagliptin hydrochloride monohydrate is a white to almost-white powder. It is freely soluble in water across the physiological pH range. Sitagliptin incorporates a single chiral centre. Enantiomeric purity is controlled routinely in the active substance by chiral HPLC.

<div style=\"page-break-after: always\"></div>

The active substance exhibits polymorphism and various polymorphic forms of sitagliptin hydrochloride including solvates have been reported in the literature. The manufacturing process of Sitagliptin hydrochloride monohydrate followed by the ASMF holder consistently produces the same polymorphic form. The pXRD method, which is part of the specifications of the active substance, is suitable to differentiate the desired polymorphic form from the other forms of sitagliptin hydrochloride. The final crystallisation conditions ensure the correct monohydrate polymorphic form is produced routinely.

The polymorphic form does not change during drug substance storage (6M data at 40°C / 75% RH and 25°C / 60% RH presented).

## 2.2.2.2. Manufacture, characterisation and process controls

Detailed information on the manufacturing process of the active substance has been provided in the restricted part of the ASMF and it was considered satisfactory. During the procedure, a Major Objection was raised to request redefinition of the starting materials. After redefinition of the initially proposed starting materials to well defined starting materials with acceptable specifications, the manufacturing process, now involving multiple chemical transformation steps, was considered acceptable.

Briefly, the manufacturing process of sitagliptin hydrochloride monohydrate consists of two parallel branches each consisting of multiple chemical transformation steps to obtain the final drug substance.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential and actual impurities were well discussed with regards to their origin and characterised. As part of the response to the MO on redefinition of starting materials, carry-over studies showing a purging of potential impurities from the redefined starting materials were presented, and the risk of mutagenic impurities from the redefined starting materials was explained. All relevant dossier sections resulting from the redefinition of starting materials were updated.

All three impurities described in the Ph. Eur. in the monograph of sitagliptin phosphate monohydrate are discussed: Impurity A (enantiomer) was characterised and is controlled via an in-house HPLC method. Impurities B and C are unspecified impurities that are measured by the related substances HPLC method.

Residual solvents and elemental impurities are discussed and batch results from three batches were provided. All discussed solvents are included in the drug substance specification with appropriate limits. Data for elemental impurities shows that all tested elements, including Rh introduced in a catalyst in one process, are well below the respective control thresholds). All elements relevant for oral dosage form have been considered.

The ASMF holder provided evidence that the intermediate, as supplied by both manufacturers (each using their own synthesis process), is of comparable and consistent quality, and results in active substance of comparable and consistent quality.

The active substance is packaged in a double transparent Low Density Polyethylene (LDPE) bag with strip seal followed by a Triple Laminated Sunlight Barrier bag (TLSB) with heat seal, kept in High Density Polyethylene (HDPE) container. The LDPE bags comply with the EU regulation EC 10/2011 as amended.

<div style=\"page-break-after: always\"></div>

## 2.2.2.3. Specification(s)

The active substance specification includes tests for: description, solubility (Ph. Eur.), identity (IR, test for chloride by Ph. Eur.), hydrochloric acid content (potentiometry), water content (KF), sulfated ash (Ph. Eur.), related substances (HPLC), enantiomeric purity (chiral HPLC), assay (HPLC), residual solvents (GC), benzene (GC), polymorph identification (PXRD) and particle size (laser diffraction).

The active substance specification complies with Ph. Eur. 2034 ('substances for pharmaceutical use'). Additionally, the specification is largely in line with Ph. Eur. monograph 2778 applicable for Sitagliptin Phosphate Monohydrate, which only differs from Sitagliptin hydrochloride monohydrate in the nature of the counter ion. All relevant quality parameters are specified.

Microbiological quality is not tested. Taking into account that the drug substance is a dry powder, the risk emanating from microbiological growth is considered as negligible. Accordingly, omission of microbiological testing is acceptable.

Residual solvents are controlled as per ICHQ3C, and relevant specifications have been established in the active substance.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay, impurities and enantiomeric purity testing has been presented.

Batch data on three consecutive production scale batches is presented. Results comply with the drug substance specification and are similar irrespective of applied process.

## 2.2.2.4. Stability

Stability data from three production scale batches of active substance from the proposed manufacturers stored in the intended commercial package for up to 24 months under long term conditions (25°C / 60% RH) and for up to 6 months under accelerated conditions (40°C / 75% RH) according to the ICH guidelines were provided. Also, photostability testing following the ICH guideline Q1B was performed.

The parameters tested are the same as for release, except sulfated ash, which is acceptable. The analytical methods used were the same as for release and are stability indicating. Stress studies were performed exposing the Sitagliptin HCl monohydrate to alkaline hydrolysis, acidic hydrolysis, oxidative conditions, photolytic conditions in solid and dissolved form, thermic energy and humidity. A significant degradation of the assay was found under base hydrolysis, acid hydrolysis and oxidative conditions. The active substance was stable during photolytic and thermal stability experiments. Mass balance and Sitagliptin peak purity were appropriate.

All tested parameters were within the specifications, and no trends were observed.

Confirmation was provided that stability studies according to long term and accelerated ICH conditions on first three production scale batches obtained by the modified manufacturing process are initiated,

The stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 36 months at a temperature not exceeding to 25°C in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished medicinal product

## 2.2.3.1. Description of the product and Pharmaceutical development

The finished product is presented as film-coated tablets containing 25 mg, 50 mg or 100 mg of sitagliptin (as hydrochloride monohydrate salt) as active substance. The different tablet strengths are appropriately differentiated by their colour, size and debossing:

- 25 mg Sitagliptin (as hydrochloride monohydrate): Pink coloured, round, levelled edge, filmcoated tablet debossed with 'S3' on one side and plain on the other side. Diameter: 6 to 6.40 mm
- 50 mg Sitagliptin (as hydrochloride monohydrate): Light beige coloured, round, bevelled edge, film-coated tablet debossed with 'S4' on one side and plain on the other side. Diameter: 8 to 8.40 mm
- 100 mg Sitagliptin (as hydrochloride monohydrate): Beige coloured, round, levelled edge, filmcoated tablet debossed with 'S7' on one side and plain on the other side. Diameter: 10 to 10.40 mm

All three strengths of tablet are manufactured from a common blend and the tablet cores have quantitatively proportional compositions.

The quality target product profile (QTPP) was defined as an immediate release dosage form, containing sitagliptin hydrochloride monohydrate equivalent to 25, 50 or 100 mg sitagliptin, with a shelf-life of at least 24 months at room temperature, bioequivalent to the reference product Januvia.

The qualitative formulation was developed in line with  the reference product and the quantity of each excipient was optimized based on design of experiments and one-factor-at-a-time studies. Assay, related substances, uniformity  of  dosage units,  disintegration  time  and dissolution  were identified  as critical quality attributes (CQAs), and therefore identified for tracking in the risk assessment.

Drug substance attributes were assessed, and the impact that each attribute could have on the drug product CQAs was subject to a risk assessment. As such, the solid-state form, particle size distribution (PSD), hygroscopicity, residual solvents, moisture content, process impurities and chemical stability were investigated.

The active substance is a BCS class I substance, hence PSD will not affect dissolution. Although PSD is not critical, a PSD specification was introduced by the finished product manufacturer, to ensure consistency of future supply of active substance batches. The active substance shows polymorphism. However, the ASMF holder consistently provides the same polymorphic form. Submitted data demonstrated stability of the polymorphic form during the tabletting process and stored under accelerated conditions (6 months at 40 °C /75%RH). Although the active substance is non-hygroscopic and the moisture content is controlled at release, the impact of moisture, and the impact of chemical stability of the active substance on the finished product attributes were judged as medium risk.

All excipients are well  known pharmaceutical ingredients and  their  quality is  compliant with  Ph. Eur. standards, except for the film-coating material which is controlled according to in-house specifications. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

A study showed the compatibility of the excipients with the active substance. Information about relevant functionality related excipient characteristics is provided.

<div style=\"page-break-after: always\"></div>

A bioequivalence study was conducted with the Sitagliptin Accord 100 mg tablets, against the reference product  Januvia  100 mg  tablets.  The  Sitagliptin Accord  100  mg  tablets  biobatch  used  in  the bioequivalence study, and were manufactured with the proposed commercial manufacturing process.

The dissolution behaviour of Sitagliptin Accord (100 mg) and the reference product Januvia 100 mg was investigated in the physiological pH range between 1.2 to 6.8 (0.1 M HCl pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8). Sink conditions could be achieved in all dissolution media due to the high solubility of the tablets. The drug substance in both test and reference tablets was observed to be rapidly dissolving (i.e. more than 85% within 15min) at all tested pHs.

Discriminatory power of the dissolution method could not be shown by testing a batch showing elevated hardness, or lower disintegrant level. Since the drug product contains a BCS class I active substances with very high solubility over the physiological pH range and with rapid or very rapid dissolution, disintegration testing is considered more discriminatory than dissolution testing according to the presented data. Therefore, disintegration testing instead of dissolution testing is included in the specification.

A comparison of the dissolution profiles of the 25 mg tablets and 50 mg tablets (which are doseproportional to the 100 mg-tablets) with the biobatch (100 mg), was performed in the same dissolution media (0.1 M HCl pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8), showing similar dissolution profiles. Consequently, a biowaiver was granted for the 25 and 50 mg strengths.

A risk  assessment of the  overall drug  product manufacturing  process was  performed to  identify  the process parameters of each unit  operation that may affect the CQAs of the final drug product. All risks were assigned as medium (or low),  except the  compression force/tablet hardness and the lubrication time of the blend, which were estimated as high risk for their potential impact on the dissolution profile of the tablets. Further experiments  were performed  subsequently for each medium and high-risk process step  to  identify  the  suitable  process parameter  range. After  detailed  experimentation and  scale-up studies, the initial manufacturing process risk assessment was updated, and the risks were reduced to an acceptable level (low) and a control strategy was established.

The  primary  packaging  for  the  finished  product  is  PVC/PE/PVDC-aluminium  blisters.  The  material complies with Ph. Eur. and EC requirements.

The primary packaging for the bulk storage of intermediates (i.e. lubricated blend, compressed tablets and coated tablets) are double lined LDPE bags kept in in-process containers.

The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## 2.2.3.2. Manufacture of the product and process controls

The manufacturing process consists of ten main steps: sifting, pre-compaction blending, blending, dry granulation,  pre-lubrication  and  lubrication,  sifting  and  milling,  blending,  compression, film  coating, packaging, along with the applied in process controls (IPCs). The process is considered to be a standard manufacturing process.

Major steps of the manufacturing process have been validated on three commercial-scale batches. It has been  demonstrated  that  the  manufacturing  process is  capable of  producing  the  finished  product  of intended  quality  in  a  reproducible  manner.  The  in-process  controls  are  adequate  for  this  type  of manufacturing process for film-coated tablets.

<div style=\"page-break-after: always\"></div>

Pre-lubrication  time  and  lubrication  time,  and  corresponding  mixing  speed,  were defined  as  critical parameters in  view  of  blend  uniformity.  Furthermore,  roller pressure  during  dry  granulation  (roller compaction) was defined as a critical parameter.

The available development data, the process validation data and batch analysis data from commercial scale batches fully support the proposed control strategy.

## 2.2.3.3. Product specification(s)

The finished product release specifications include appropriate tests for this kind of dosage form: description, identification (HPLC and UV), identification of titanium dioxide (colour test), identification of iron oxide (colour test), identification of chloride (precipitation), assay (HPLC), degradation products (HPLC), water content (Ph. Eur. 2.5.32), uniformity of dosage units (Ph. Eur. 2.9.40), disintegration (Ph. Eur. 2.9.3) and microbial quality (Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13).The limits for individually specified impurities as well as unspecified degradation products are in accordance with the Ph. Eur. monograph for Sitagliptin tablets. Other impurity are specified with limits  complying with ICH Q3B. During the procedure, the specification for total impurities and for water content were tightened by the applicant.

The potential presence of elemental impurities in the finished product was assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Supportive batch analysis data on 3 batches, generated with an ICP-MS method, was provided, demonstrating that each relevant elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented supportive batch data, it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

The risk evaluation concerning the presence of nitrosamine impurities in the finished product was initially assessed as not sufficiently comprehensive, and a MO was raised, to request the Applicant to consider all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020)  and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004-  Nitrosamine impurities in human medicinal products' (EMA/369136/2020).  The Applicant updated the risk assessment to include the discussion on potential nitrosamines likely to be introduced based on the manufacturing process of the drug substance and interactions between the components of the drug substance, excipients and packaging materials. All nitrosamines that could potentially be formed taking into account all parent amine entities (secondary, tertiary and quaternary) that could be present in the components of the drug product (drug substance, excipients, water and packaging materials) have been considered. Based on the additional information provided, overall it was accepted that no risk was identified of the possible presence of nitrosamine impurities in the active substance or the related finished product. This is sufficient and confirmatory testing is not required. The batch results provided by the Applicant (NDMA, NDEA, NDIPA, NEIPA and NDBA in three active substance batches, and NDMA and NDEA in 6 finished product batches for each strength) are considered supportive. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

For each of  the strengths, batch analysis  results were provided  for  3 batches  manufactured at commercial scale confirming  the  consistency of  the  manufacturing  process and  its  ability  to  manufacture  to  the intended product specification.

<div style=\"page-break-after: always\"></div>

## 2.2.3.4. Stability of the product

For each of the strengths, stability data from three commercial scale batches of finished product stored for  up  to  24  months  under  long  term  conditions  (25°C  /  60%  RH)  and  for  up  to  6  months  under accelerated conditions  (40°C  /  75%  RH)  according  to  the  ICH  guidelines were  provided. The  tablet batches  are  identical  to  those  proposed  for  marketing  and  were  packed in  the  primary  packaging proposed for marketing.

Additionally, stability data from the same tablet batches stored for up to  12 months  under long term conditions (25°C / 60% RH) and for up to 6 months under accelerated conditions (40°C / 75% RH) in bulk  pouches (500  count)  representative of  the  laminated  bulk pouches  (5000  count)  used for bulk storage of the coated tablets, were provided.

Samples were tested for the stability indicating parameters. The analytical procedures used are stability indicating. No significant changes and no trends have been observed over the study period.

In addition, one batch per strength was exposed to light as defined in the ICH Guideline on Photostability Testing  of  New  Drug  Substances  and  Products.  No  photolytic  degradation  of  the  drug  product  was observed.

Based on available stability data, the proposed shelf-life of 3 years, with no special storage conditions, as stated in the SmPC (sections 6.3 and 6.4), and the proposed holding time of 12 months for the bulk packed tablets, prior to primary blister packaging, are acceptable.

## 2.2.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.2.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

During the procedure, two Major Objections were raised. A first one to request redefinition of the starting materials due to the fact that the synthetic process of the active substance as initially described in S.2.2 comprised only two chemical transformation steps. The starting materials were redefined as requested.

A second MO was raised on the risk evaluation concerning the presence of nitrosamine impurities in the finished product, since it initially was not sufficiently comprehensive. The Applicant provided a revised risk assessment and it was accepted that no risk was identified of the possible presence of nitrosamine impurities in the active substance or the related finished product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation(s) for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

Pharmacodynamic, pharmacokinetic and toxicological properties of sitagliptin are well known. As sitagliptin is a widely used, well-known active substance, the applicant has not provided additional studies and further studies are not required. A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The impurity profile has been discussed and was considered acceptable.

Therefore, the CHMP agreed that no further non-clinical studies are required.

The generic formulation Sitagliptin Accord contains a different salt form of the active substance sitagliptin (hydrochloride monohydrate) as compared to the reference product, Januvia, which contains sitagliptin as the phosphate salt. Although the generic product has a different salt form, according to Article 10(2) of Directive 2001/83/EC (as amended), 'the different salts, esters, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with regard to safety and/or efficacy.' Following the assessment of all data provided, the CHMP concluded that sitagliptin hydrochloride does not differ significantly with regard to safety and efficacy in comparison with the reference medicinal product.

## 2.3.2. Ecotoxicity/environmental risk assessment

No Environmental Risk Assessment (ERA) studies were submitted. This was justified by the applicant as the introduction of Sitagliptin Accord, 25 mg, 50 mg, 100 mg film-coated tablets, manufactured by Accord Healthcare S.L.U. is considered unlikely to result in any significant increase in the combined sales volumes for all sitagliptin containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar.

## 2.3.3. Discussion on non-clinical aspects

The range of non-clinical data presented in the dossier is appropriate for a generic application. The nonclinical aspects of the SmPC are in line with the SmPC of the reference product.

The  CHMP  considers  that  the  non-clinical  overview is  based  on  up-to-date  and  adequate  scientific literature. It is agreed that no further non-clinical studies are required.

Taking into account the data submitted by the applicant and the established essential similarity with the reference product Januvia, the use of sitagliptin as indicated is not likely to present risks to the environment, hence no further environmental risk assessment is considered necessary for this generic product.

## 2.3.4. Conclusion on the non-clinical aspects

A summary of the literature with regard to non-clinical data of Sitagliptin Accord and justifications that the different salt of the active substance does not differ significantly in properties with regard to safety and efficacy of the reference product was provided and was accepted by the CHMP. This is in accordance with the relevant guideline and additional non-clinical studies were not considered necessary. The product is considered approvable from a non-clinical viewpoint.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

This application concerns a generic application of a centrally authorised medicinal product according to Art. 10(1) of Directive 2001/83/EC as amended. The Applicant has developed Sitagliptin Accord filmcoated tablets as generic to the reference medicinal product Januvia 25 mg, 50 mg, 100 mg filmcoated tablets.

Relevant for the assessment are the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98) as well as the Guideline on Bioanalytical method validation (EMEA/CHMP/EWP/192217/09)  and Sitagliptin film-coated tablets 25, 50 and 100 mg product-specific bioequivalence guidance (EMA/CHMP/158934/2016).

The applicant did not receive CHMP Scientific Advice pertinent to the clinical investigation.

Human pharmacology, efficacy and safety of sitagliptin are well known. The Clinical Overview on the clinical pharmacology, efficacy and safety is acceptable. The submitted literature references included in the overview are considered appropriate and relevant for the proposed indications. The proposed generic medicinal product contains a different salt of the active substance (hydrochloride monohydrate) as compared to the reference medicinal product (phosphate monohydrate). However, following the assessment of the data and justifications provided the CHMP concluded that the different salt of the active substance does not differ significantly in properties with regard to safety and efficacy of the reference product has been provided.

Since this is a generic application, the Applicant performed a bioequivalence study to show essential similarity of the test product to the originator.

The Applicant has not submitted any other clinical studies and no further clinical studies are required according to the Directive 2001/83/EC.

The proposed indication and posology are in line with the reference product.

## GCP aspect

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## Exemption

A strength biowaiver was requested for Sitagliptin Accord 25 mg and 50 mg film-coated tablets.

The Applicant made reference to the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1 - January. 2010) according to which Sitagliptin 25 mg and 50 mg film-coated tablets satisfy the conditions for waiver of the bioequivalence study conducted with 100 mg film-coated tablets as discussed below:

a) Sitagliptin 25 mg, 50 mg and 100 mg film coated tablets are manufactured by the same drug product manufacturer process.

b) The qualitative composition of the different strengths (25 mg, 50 mg and 100 mg) is the same.

c) The composition of the 25 mg, 50 mg and 100 mg strengths are quantitatively proportional, i.e. the ratio between the amounts of each excipient to the amount of Sitagliptin is the same for all strengths.

<div style=\"page-break-after: always\"></div>

d) Considering the Biopharmaceutical classification system of the product, Sitagliptin is a BCS Class I compound demonstrating high solubility compound with complete absorption.

- e) The results of in vitro dissolution tests at three different buffers (normally pH 0.1 N HCl, 4.5 and 6.8) of Sitagliptin 25 mg and 50 mg film-coated tablets are comparable with Sitagliptin 100 mg filmcoated tablets (test product of bio-equivalence study).

f) According to the EMA guideline on the Investigation of Bioequivalence (Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**, (Section 4.1.6 - strength to be investigated)), for drug product with linear pharmacokinetics of the active substance, for which all the above conditions a) to c) and e) the bioequivalence study should in general be conducted at the highest strength.

According to the current publications, the pharmacokinetics of Sitagliptin is linear as follows:

- Plasma AUC of sitagliptin increased in a dose-proportional manner, and Sitagliptin shows linear pharmacokinetics. [Januvia, SmPC (2018]
- The EU product-specific bioequivalence guidance of Sitagliptin states that due to the linear pharmacokinetics of Sitagliptin, bioequivalence study should be conducted at the highest strength (100 mg) and other strength(s) (25 mg &amp; 50 mg) are eligible for bio-waiver [Sitagliptin, EU Guidance 2016].

Based on above justifications, the bioequivalence study was conducted on the highest strength i.e. 100 mg and a Bio-Waiver was requested for the lower strengths of 50 mg and 25 mg.

The Applicant provided additional data during the procedure to demonstrate that the applied for generic medicinal product satisfy the BCS-based biowaiver requirements, in line with Appendix III of Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010).

The extent of absorption of sitagliptin is &gt;85 % and the absorption/permeability criteria for a BCS class I biowaiver is fulfilled. The qualitative composition of the test and reference products is similar. However, the proposed product contains sitagliptin HCl as opposed to Januvia where sitagliptin phosphate is used. None of the excipients are known to affect the bioavailability and the use of different salts is considered acceptable. In addition, sitagliptin is not considered to be a narrow therapeutic index drug.

In conclusion, the demonstration for a BCS class I (Biopharmaceutics Classification System) based biowaiver can be accepted from a clinical point of view.

## · Tabular overview of clinical studies

To support the application, the applicant has submitted two bioequivalence studies

<div style=\"page-break-after: always\"></div>

Table5.2TabularListingofallClinicalStudies

<!-- image -->

| Type Study of   | Study Identifier   | Location of Study report   | Objective(s) of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Subjects    | Nunber ofStudyDesign&type of control                                                                                                                                                                                 | Test Product(s); Dosage Regimen; Route of Adninistration                                                                                                                                                                        | Healthy Subjects                            | Duration Treatment of   | Study Status; Type of Report   |
|-----------------|--------------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------------|--------------------------------|
|                 | BEPCLPL-027-19     |                            | Primary Objective: Toassess thebioequivalence of Sitagliptin100mgfilmcoated Tablets ofLauruslabslimited India with Januvia (sitagliptin) 100 mg film coated Tablets of Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom, in healthy, Moduleadult, human subjects under 5, 5.3.1.2fasting conditions. Secondary objective: Tomonitorthesafety and tolerabilityofasingledose administeredinhealthy,human adult subjects under fasting conditions. | 36 subjects | An open-label, balanced, randomized,two- treatment, two- sequence, two-period, crossover, single dose oral bioequivalence shudyinnormal healthy, adult, human subjects under fasting conditions. Treatmentcontrolled | Test Product (T): Sitagliptin 100 mg filmcoatedTablets One Tablet was administered orally. [Batch No. E1903731] Reference Product(R): Januvia 100 mg film coated Tablets One Tablet was administered orally. [Lot No.: S000191] | Normal, healthy, adult, human male subjects | Single Dose             | Completed; Abbreviated         |

In order to confirm the reliability of the conclusion of the initial BE study, the Applicant performed a new BE study (Study Protocol No P-62020) using the same unexpired lots of the Test and the Reference product that were used in the previous BE study.

## 5.2 Listing of Clinical Studies

<!-- image -->

| Type of the Study    |   Study Identifier | Location of Study Report                   | Objectives of the study                                                                                                                                                                                                                                                                                                                                                                                                | Shudy Design and Type of Control                                                                                                                                                                                                      | Test Product (s) Dose Regimen; Route of Administration                                                                                                                                                                               | No of Subjects                                             | Healthy Subjects or Dingnosis of Patients   | Duration of Treatment                       | StudyStatus and Type of Report     |
|----------------------|--------------------|--------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------|
| Bioequivalence Study |              62020 | mochle Refer 5.3.1.2, sections 1.0 to 15.0 | To assess the bioequivalence of Sitagliptin 100 mg Film Coated Tablets of Lawus Labs Limited, India, comparing with that of Januvia00 100 mg Film of Merck Sharp & Dohme coated tablets (sitagliptin) Ltd, Hertford Road Kingdom in healthy, adult, Hoddesdon, Hertfordshire, EN11 9BU, Umited human subjects umder fasting conditions. To monitor adverse events and ensuwre the safety and tolerability of subjects. | Study Desigu: An open label, balaucedrandomized two-treatment, two- period, two-sequence, single dose, crossover oralbioequivalence shudy in bealty,adt huwan subjects umder fasting conditions. Type of Control: Treatment contolled | Test product (T): (01 x Sitagliptin 100 mg Film Coated Tablets.Administered orally 36 emrolled Batch No. E1903731 Reference product (R): (01 x Jamuvia*100 mg Film coated tablets (sitagliptin)) Administered orally Lot No: S000191 | and 35 considered subjects for PK and statistical analysis | Healthy, adlt, hman subjects                | Single 100 mg dose of tablet in period each | Abbreviated Completed, application |

## 2.4.2. Clinical pharmacology

## 2.4.2.1. Pharmacokinetics

## Study PCLPL-027-19

## Study resign

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral bioequivalence study of Sitagliptin 100 mg film coated Tablets of Laurus Labs. Limited, India with Januvia (sitagliptin)  100 mg film coated tablets of Merck Sharp &amp; Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, United Kingdom, in healthy, adult, human subjects under fasting conditions.

<div style=\"page-break-after: always\"></div>

The design of the study is in line with the requirements of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 01 - January 2010) and with Sitagliptin productspecific bioequivalence guidance (EMA/CHMP/158934/2016),  therefore, it is considered appropriate.

The test product is an immediate release formulation; thus, a single dose bioequivalence study is appropriate.

According to the SmPC, the reference product can be taken with or without food. Thus, the bioequivalence study conducted under fasting conditions is acceptable.

The bioequivalence study was conducted with the highest strength which is also in line with Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 01 - January 2010) and with Sitagliptin product-specific bioequivalence guidance (EMA/CHMP/158934/2016).

Plasma samples are collected over 48 hours. Frequent sampling was planned around expected tmax (1-4 hours).

Considering the median tmax occurring 1 to 4 hours post-dose, the sampling period and the sampling scheme seems adequate to estimate the primary PK parameters of sitagliptin.

Since AUC0-t covers at least 80% of AUC0-∞ , the sampling schedule covers the plasma concentration time curve long enough.

Tmax was not observed in any subject in the first sample time point.

The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin is approximately 12.4 hours, thus the washout period of 08 days is more than 5 half-life of the active substance.

## Pharmacokinetic Variables

The primary pharmacokinetic parameters were: Cmax and AUC0-t.

The secondary pharmacokinetic parameters were: AUC0-∞ , Tmax, Kel, T1/2, %AUCextrapolation and AUCt/AUC ∞ .

The pharmacokinetic parameters are adequate for a bioequivalence trial with immediate-release formulation.

## Statistical methods

Statistical analysis was performed on ln-transformed pharmacokinetic parameters by using software SAS Version 9.4. Least square mean differences (Test to Reference) of the test to reference formulation for the pharmacokinetic parameters Cmax and AUC0-t for Sitagliptin were estimated using SAS procedure.

Individual and Mean plasma concentration vs. time plots were generated on both Linear and Semi-log axis for Sitagliptin.

Descriptive statistics (no. of subjects analysed, arithmetic mean, geometric mean, standard deviation, coefficient of variation, median and maximum) of all the primary pharmacokinetic parameters were calculated and reported for Sitagliptin.

Actual time points of the sample collection were used for the calculation of PK parameters. All concentration values Below Limit of Quantification were set to zero for all pharmacokinetic calculations. Missing sample values (MS) or non-reportable values (NRV) of the plasma concentration data were treated as 'missing values' and reasons for their missing were documented. Further these missing

<div style=\"page-break-after: always\"></div>

values were kept blank in Phoenix ®  WinNonlin version 8.1 since this software recognizes this blank cell as 'Missing' and does not consider for the estimation of pharmacokinetic parameters.

Individual AUC0-t parameters were calculated using the linear trapezoidal rule.

The Ln-transformed pharmacokinetic parameters Cmax and AUC0-t at a significance level of 5% (alpha =0.05) of Sitagliptin was subjected to Analysis of Variance (ANOVA) by using PROC GLM.

ANOVA model include Sequence, treatment and Period as fixed effects and Subject (Sequence) as a random effect. Sequence effect has been tested using Subject (Sequence) as error term.

Non-parametric analysis of tmax was performed on untransformed data.

Two one-sided 90% confidence interval for the ratio of mean between drug formulations has been calculated for Ln-transformed data of Cmax and AUC0-t of Sitagliptin.

Ratio of Geometric least square means for Sitagliptin of test and reference formulations has been computed and reported for Ln-transformed pharmacokinetic parameters Cmax, and AUC0-t.

Ratio (%) of Test and Reference formulations for each individual subject has been provided for untransformed pharmacokinetic parameters Cmax and AUC0-t for Sitagliptin.

## Criteria for conclusion of bioequivalence

The acceptance criteria for bioequivalence were that the entire confidence intervals for the difference of means of Ln-transformed Cmax and AUC0-t should be within 80.00% -125.00%. Standard bioequivalence criteria are proposed for the primary pharmacokinetic endpoints Cmax and AUC0-t, which is adequate.

## Results

Table 1 Pharmacokinetic parameters for Sitagliptin (non-transformed values)

|                              | Test                                                                                                                                                                                                                              | Test                                                                                                                                                                                                                              | Reference                                                                                                                                                                                                                         | Reference                                                                                                                                                                                                                         |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pharmacokin etic parameter   | arithmetic mean geometric mean                                                                                                                                                                                                    | SD CV%                                                                                                                                                                                                                            | arithmetic mean geometric mean                                                                                                                                                                                                    | SD CV%                                                                                                                                                                                                                            |
| AUC(0-t) (ng*hr/mL)          | 5475.4527 5390.1249                                                                                                                                                                                                               | ± 996.79309 18.20%                                                                                                                                                                                                                | 5496.5514 5409.4608                                                                                                                                                                                                               | ± 1000.5077 2 18.20%                                                                                                                                                                                                              |
| AUC(0- ∞) (ng*hr/mL)         | 5607.5178 5516.5567                                                                                                                                                                                                               | ± 1045.584 07 18.65                                                                                                                                                                                                               | 5632.0134 5539.9239                                                                                                                                                                                                               | ± 1043.4890 2 18.53%                                                                                                                                                                                                              |
| Cmax (ng/mL)                 | 477.7512 470.0231                                                                                                                                                                                                                 | ± 86.20852 18.04%                                                                                                                                                                                                                 | 517.2164 491.9287                                                                                                                                                                                                                 | ± 188.22029 36.39%                                                                                                                                                                                                                |
| Tmax* (hr)                   | 4.00                                                                                                                                                                                                                              | 1.33 - 8.00                                                                                                                                                                                                                       | 4.67                                                                                                                                                                                                                              | 0.75 - 8.00                                                                                                                                                                                                                       |
| AUC 0-t AUC 0- ∞ C max T max | area under the plasma concentration-time curve from time zero to t hours> area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration (* median, range) | area under the plasma concentration-time curve from time zero to t hours> area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration (* median, range) | area under the plasma concentration-time curve from time zero to t hours> area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration (* median, range) | area under the plasma concentration-time curve from time zero to t hours> area under the plasma concentration-time curve from time zero to infinity maximum plasma concentration time for maximum concentration (* median, range) |

<div style=\"page-break-after: always\"></div>

Table 2 Statistical analysis for Sitagliptin (ln-transformed values)

| Pharmacokinetic parameter                  | Geometric Mean Ratio Test/Reference%       | Confidence Intervals                       | CV%*                                       |
|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| AUC(0-t) (ng*hr/mL)                        | 99.64                                      | 97.61 - 101.72                             | 5.02                                       |
| Cmax (ng/mL)                               | 95.55                                      | 88.42 - 103.25                             | 19.04                                      |
| * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares | * estimated from the Residual Mean Squares |

Figure 2: Mean  plasma concentration (ng/mL) of Sitagliptin vs. Time (hr) plot for Test (T) and Reference (R) formulations (N=34):

## PCLPL-027-19 (Sitagliptin)

Figure 3: Mean  logarithmic (ng/ml) of Sitagliptin vs. Time (hr) plot for Test (T) and Reference (R) formulations (N=34)

<!-- image -->

## PCLPL-027-19 (Sitagliptin)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 3: ANOVA Summary Table - Sitagliptin

| Sitagliptin   | Sitagliptin     | Sitagliptin     |
|---------------|-----------------|-----------------|
| Parameter's   | ANOVA p-values* | ANOVA p-values* |
| Effects       | C max           | AUCo-t          |
| Sequence      | 0.2188          | 0.2700          |
| Period        | 0.9042          | 0.1529          |
| Treatment     | 0.3270          | 0.7705          |

The pharmacokinetic parameter data including the confidence intervals and point estimates presented by the Applicant are in line with the acceptance criteria of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010). Linear and log-linear plots have been submitted. The 90% confidence intervals for the ln-transformed values for AUC0-t and Cmax were within the 80.00 - 125% limit and are considered acceptable.

The Applicant did not report any statistically significant sequence, period or treatment effect.

## Safety data

Safety parameters were assessed in all 36 randomized subjects throughout the study until completion. Thus, the safety population comprise of total 36 randomized subjects.

A total of two (02) adverse events of vomiting were reported by two (02) subjects during the study. All adverse events were possible related to the study drug and mild in nature. All the adverse events were resolved. The reported adverse events of vomiting are already described in the SmPC of the reference product.

There were no clinically significant findings in the vital signs assessment or the laboratory tests in any of the subjects in the study.

Administrations of test and reference products to healthy subjects were safe and well tolerated with no apparent differences in safety profiles.

## Study 62020

## Study design

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, and crossover oral bioequivalence study of Sitagliptin 100 mg Film Coated Tablets of Laurus Labs Limited, India, comparing with that of Januvia 100 mg Film coated tablets (sitagliptin) of Merck Sharp &amp; Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire, ENl l 9BU, United Kingdom in healthy, adult, human subjects under fasting conditions.

The design of the study is in line with the requirements of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 01 - January 2010) and with Sitagliptin productspecific bioequivalence guidance (EMA/CHMP/158934/2016),  therefore, it is considered appropriate.

The test product is an immediate release formulation; thus, a single dose bioequivalence study is appropriate.

<div style=\"page-break-after: always\"></div>

According to the SmPC, the reference product can be taken with or without food. Thus, the bioequivalence study conducted under fasting conditions is acceptable.

The bioequivalence study was conducted with the highest strength, which is also in line with Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 01 - January 2010) and with Sitagliptin product-specific bioequivalence guidance (EMA/CHMP/158934/2016).

Plasma samples are collected over 48 hours. Frequent sampling was planned around expected tmax (14 hours).

Considering the median tmax occurring 1 to 4 hours post-dose, the sampling period and the sampling scheme seems adequate to estimate the primary PK parameters of sitagliptin.

Since AUC0-t covers at least 80% of AUC0-∞ , the sampling schedule covers the plasma concentration time curve long enough.

Tmax was not observed in any subject in the first sample time point.

The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin is approximately 12.4 hours, thus the washout period of 08 days is more than 5 half-life of the active substance.

The choice of the reference product is appropriate.

In this new performed BE study the same batch of the test product, and reference product have been used. This is agreed as the batches are unexpired.

Certificates of analysis have been provided and the difference in content of active substance between reference and test product is less than 5.0%.

## Pharmacokinetic Variables

The primary pharmacokinetic parameters are: Cmax and AUC0-t.

The secondary pharmacokinetic parameters are: AUC0-inf, AUCt/AUCinf, Tmax, t1/2, Residual Area and Kel.

The pharmacokinetic parameters are adequate for a bioequivalence trial with immediate-release formulation.

## Statistical methods

For Sitagliptin, analysis of variance was performed on the ln-transformed data Cmax, AUC0-t and AUC0inf. All ANOVA were performed with SAS ®  Studio 3.6 (Basic Edition), (SAS ®  Institute Inc. USA) software.

The model included group, sequence, sequence*group, period (group), treatment, treatment*group and subject (sequence*group) as fixed effects.

## Criteria for conclusion of bioequivalence

The acceptance criteria for bioequivalence were that the entire confidence intervals for the difference of means of Ln-transformed Cmax and AUC0-t should be within 80.00% -125.00%. Standard bioequivalence criteria are proposed for the primary pharmacokinetic endpoints Cmax and AUC0-t, which is adequate.

## Results

Subject 28 was detected as an outlier for Cmax. The results include the outlier.

<div style=\"page-break-after: always\"></div>

Table 09: Summary of Pharmacokinetic Results

| Parameters        | Test (T)           | Test (T)   | Test (T)   | Reference (R)      | Reference (R)   | Reference (R)   |
|-------------------|--------------------|------------|------------|--------------------|-----------------|-----------------|
| Parameters        | Mean ± SD          | CV (%)     | N          | Mean ± SD          | CV (%)          | N               |
| C imax (ng/mL)    | 344.09 ± 64.786    | 18.828     | 35         | 343.67 ± 66.172    | 19.255          | 35              |
| AUCt (hr*ng/mL)   | 3817.401 ± 627.564 | 16.440     | 35         | 3831.205 ± 628.346 | 16.401          | 35              |
| AUCinf (hr*ng/mL) | 3921.370 ± 674.870 | 17.210     | 35         | 3936.224± 673.993  | 17.123          | 35              |
| tmax* (hr)        | 3.00 (1.00 - 5.52) | 40.59      | 35         | 3.00 (1.00 - 6.00) | 47.01           | 35              |
| t1/2 (hr)         | 9.20 ± 1.60        | 17.39      | 35         | 9.20 ± 1.52        | 16.53           | 35              |
| Kel (hr)          | 0.0772 ± 0.0117    | 15.1206    | 35         | 0.0773 ± 0.0122    | 15.8041         | 35              |
| Residual Area     | 0.025 ± 0.014      | 55.342     | 35         | 0.026± 0.012       | 45.089          | 35              |
| AUC/AUCinf        | 0.975 ± 0.014      | 1.439      | 35         | 0.974 ± 0.012      | 1.189           | 35              |

Table 10: 90% Confidence Intervals of Geometric Least Square Mean Ratio

|                   | Least square Geo Means   | Least square Geo Means   | T/R Ratio (%)   | 90% Confidence Intervals   | 90% Confidence Intervals   | Power (%)   | Intra subject CV   |
|-------------------|--------------------------|--------------------------|-----------------|----------------------------|----------------------------|-------------|--------------------|
| Parameter         | Test (T)                 | Reference (R)            | T/R Ratio (%)   | Lower (%)                  | Upper (%)                  |             | (%)                |
| max (mg/mL)       | 331.3346                 | 338.0279                 | 98.02           | 93.15                      | 103.15                     | 100.0       | 12.0               |
| AUCt (hr*ng/mL)   | 3688.2863                | 3729.5149                | 98.89           | 97.34                      | 100.48                     | 100.0       | 3.7                |
| AUCinf (hr*ng/mL) | 3779.0926                | 3821.4508                | 98.89           | 97.34                      | 100.47                     | 100.0       | 3.7                |

<div style=\"page-break-after: always\"></div>

## 14.2.2 Graphs

Figure l: Linear Plot of Mean Plasma Concentration versus Time for all subjects Sitagliptin

Time Vs Mean [62020.Sitaglptin)

<!-- image -->

Figure 2: Semi-log Plot of Mean Plasma Concentration versus Time for all subjects Sitagliptin Time Vs Log Mean [62020.Sitaglptin)

<!-- image -->

Table 11: p-Value for Pharmacokinetic Parameters

| IIaineffects   | LnC imax   | LnAUCt   | LnAUCinf   |
|----------------|------------|----------|------------|
| Sequence       | 0.0224*    | 0.0029*  | 0.0028*    |
| Period (group) | 0.0121     | 0.3251   | 0.4001     |
| Treatment      | 0.5111     | 0.2445   | 0.2409     |

The significant sequence effects detected for all PK parameter AUC0-t, Cmax and AUC(0∞) have been explained that might be due to unbalanced sequences. An adequate washout period was established and the pre-dose samples do not show any detectable levels (&gt; 5% of Cmax) of the drugs in all the volunteers, therefore the presence of sequence effect can be accepted and considered not to influence the comparison of the formulations.

<div style=\"page-break-after: always\"></div>

The significant period by group detected for the LnCmax is considered not to influence the results of the BE study as no significant treatment effect was associated and the study was balanced.

The study satisfies all the scientific and statistical criteria (for example protocol, validation, concentration data, statistical analysis, confidence interval).

The pharmacokinetic parameter data including the confidence intervals and point estimates presented by the Applicant are in line with the acceptance criteria of the Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010). Linear and semi-log plots have been submitted for the mean plasma concentration versus time for all subjects. The issue was solved.

The 90% confidence intervals for the ln-transformed values for AUC0-t and Cmax were within the 80.00 - 125% limit and are considered acceptable.

The results without the outlier have been also provided. In addition, in this case, the acceptance criteria for bioequivalence have been fulfilled as the entire confidence intervals for the difference of means of Ln-transformed Cmax and AUC0-t are within 80.00% -125.00%.

## Safety data

Safety parameters have been assessed in all 36 randomized subjects

A total of three (03) AEs, two (02) of headache and 01 AE of generalized rash, were reported by three (03) subjects during study. Out of these, two (02) AE's of headache and one (01) AE of generalized rash were considered possibly related to the study drug and were moderate in nature. All these AE's were resolved. Headache and rash are adverse reactions included in the SmPC of the Reference product.

There were no clinically significant findings in the vital signs assessment or the laboratory tests in any of the subjects in the study.

Administrations of test and reference products to healthy subjects were safe and well tolerated with no apparent differences in safety profiles.

## 2.4.2.2. Pharmacokinetic conclusion

It has been demonstrated from literature data that the extent of absorption of sitagliptin is &gt;85 % and the absorption/permeability criteria for a BCS class I biowaiver is fulfilled. In addition, the high solubility of the drug substance has been demonstrated in a carried out solubility study using shakeflask method according to the guideline.

Based on the solubility study and literature information both Sitagliptin HCl monohydrate and Sitagliptin phosphate monohydrate belong to BCS class I and therefore, in vitro data could be used to justify the BCS- biowaiver and to confirm the bioequivalence between the test and reference medicinal products. Comparative dissolution profiles between the bio-batch and additional strengths of test formulation and in addition for each strength in comparison with respective of the reference medicinal product demonstrated the similarity without further mathematical evaluation as more than 85% of the labelled amount of the drug was released within 15 minutes.

The BCS-based biowaiver requirements according to Appendix III of Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010) are considered fulfilled.

In order to confirm the reliability of the conclusion of the initial BE study, the Applicant conducted an additional supportive bioequivalence study using the same unexpired Test and Reference bio-batches that have been used in the initial BE study. The 90% confidence intervals of the ratios are within the

<div style=\"page-break-after: always\"></div>

acceptance range (0.80-1.25)  for the ln transformed Cmax, AUC0-t and AUC0∞ th erefore the  results of the new study confirmed the bioequivalence between test and reference products.

## 2.4.2.3. Pharmacodynamics

No new pharmacodynamic studies were presented and no such studies are required for this application.

## 2.4.2.4. Post marketing experience

No post-marketing data are available. The medicinal product has not been marketed in any country.

## 2.4.3. Discussion on clinical aspects

To support the application, the Applicant provided one bioequivalence study and literature data on clinical pharmacology, efficacy and safety, which is considered appropriate for a generic marketing authorisation application. Sitagliptin Accord contains a different salt of the active substance (hydrochloride monohydrate) in comparison with the reference medicinal product (phosphate monohydrate). A justification that the different salt of the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product has been provided and is considered acceptable.

The bioequivalence study was a single dose, open-label, balanced, randomized, two-treatment, twosequence, two-period, crossover study in healthy, adult under fasting conditions to demonstrate essential similarity of Sitagliptin 100 mg film coated tablets with Januvia (sitagliptin) 100 mg film coated tablets.

According to the SmPC of the reference product, Sitagliptin can be taken with or without  food. Sitagliptin is a high solubility compound with complete absorption with linear pharmacokinetics over the therapeutic dose range and the use of highest strength is recommended in line with the Product specific bioequivalence guideline. Therefore, the selection of the highest dose, 100 mg, to be used in the bioequivalence study under fasting conditions is justified and in accordance with the guidelines.

Overall, the study design is acceptable and in line with the pharmacokinetic properties of Sitagliptin.

The sampling period was sufficient, the sampling schedule and wash-out period were adequate taking into account the tmax and apparent terminal t1/2. Since AUC0-t covers at least 80% of AUC0-∞ , the sampling schedule covers the plasma concentration time curve long enough.

The population was chosen according to the guidelines. Bioanalytical method had satisfactory performance and was adequately validated. The pharmacokinetic and statistical methods applied were appropriate for a single-dose study.

The 90% confidence intervals for ln-transformed pharmacokinetic variables Cmax and AUC0-t were within the conventional bioequivalence range of 80.00% to 125.00%.

Both formulations were well tolerated in the BE study.

During the procedure, the Applicant applied for a BCS biowaiver and performed an additional supportive bioequivalence study using the same unexpired Test and Reference bio-batches that have been used in the initial BE study in order to confirm the reliability of the conclusion of the initial BE study.

<div style=\"page-break-after: always\"></div>

The Applicant also demonstrated that the applied for generic medicinal product satisfy the BCS-based biowaiver requirements as mentioned in Appendix III of Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010). This is considered acceptable.

The acceptance criteria for the new performed bioequivalence study have been fulfilled as the entire confidence intervals for the difference of means of Ln-transformed Cmax and AUC0-t are within 80.00% 125.00%.

Additionally, the applicant requested a biowaiver for Sitagliptin Accord 25 mg and 50 mg film-coated tablets. To support the request, a justification and results of comparative dissolution tests have been provided. The in vitro dissolution tests comparing the in vitro dissolution similarity between additional strengths and the test bio-batch over physiological pH range were conducted. Comparative dissolution profiles demonstrated that the bio-batch and additional strengths of test formulation were essentially similar over the physiological pH range. The Applicant has not calculated the similarity factor since more than 85% of the labelled amount of the drug was released within 15 minutes, based on average value for dissolution from 12 units. Therefore, dissolution profiles can be accepted as similar, without further mathematical calculations. In conclusion, the in vivo bioequivalence study for strengths 25 mg and 50 mg can be waived because all the biowaiver criteria have been fulfilled.

## 2.4.4. Conclusions on clinical aspects

Based on the presented bioequivalence study(ies) Sitagliptin Accord is considered bioequivalent with Januvia.

A summary of the literature with regard to clinical data of Sitagliptin Accord and justifications that the different salt of the active substance does not differ significantly in properties with regard to safety and efficacy of the reference product was provided and was accepted by the CHMP. This is in accordance with the relevant guideline and additional clinical studies were not considered necessary.

A benefit/risk ratio comparable to the reference product can therefore be concluded from a clinical viewpoint.

## 2.5. Risk Management Plan

## 2.5.1. Safety concerns

## Summary of safety concerns

The applicant identified the following safety concerns in the RMP:

Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns              |
|------------------------------|-----------------------------------------|
| Important identified risks   | None                                    |
| Important potential risks    | Pancreatic cancer                       |
| Missing information          | Exposure during pregnancy and lactation |

## 2.5.2. Pharmacovigilance plan

No additional pharmacovigilance activities.

<div style=\"page-break-after: always\"></div>

## 2.5.3. Risk minimisation measures

None.

## 2.5.4. Conclusion

The CHMP and PRAC considered that the risk management plan version 1.0 is acceptable.

## 2.6. Pharmacovigilance

## 2.6.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.6.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Product information

## 2.7.1. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Januvia. The bridging report submitted by the applicant has been found acceptable.

## 3. Benefit-risk balance

This application concerns a generic version of sitagliptin 25 mg, 50 mg and 100 mg film-coated tablet. The reference product Januvia is indicated for the treatment of adult patients with type 2 diabetes mellitus, to improve glycaemic control:

as monotherapy:

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with:

- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
- a peroxisome proliferator-activated receptor gamma (PPAR γ ) agonist (i.e. a thiazolidinedione) when use of a PPAR γ agonist is appropriate and when diet and exercise plus the PPAR γ agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with:

<div style=\"page-break-after: always\"></div>

- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
- a PPAR γ agonist and metformin when use of a PPAR γ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

No non-clinical studies have been provided for this application but an adequate summary of the available non-clinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics as well as the efficacy and safety of the active substance; the applicant's clinical overview on these clinical aspects based on information from published literature was considered sufficient.

The bioequivalence study forms the pivotal basis with a single dose, open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover study in healthy, adult under fasting conditions. The study design was considered adequate to evaluate the bioequivalence of this formulation and was in line with the respective European requirements. Choice of dose, sampling points, overall sampling time as well as wash-out period were adequate. The analytical method was validated. Pharmacokinetic and statistical methods applied were adequate.

The test formulation of Sitagliptin Accord 100 mg film-coated tablets met the protocol-defined criteria for bioequivalence when compared with the Januvia (sitagliptin) 100 mg film coated tablets. The point estimates and their 90% confidence intervals for the parameters AUC0-t and Cmax were all contained within the protocol-defined acceptance range of [range, e.g. 80.00 to 125.00%]. Bioequivalence of the two formulations was demonstrated.

The Applicant also demonstrated that the applied for generic medicinal product satisfy the BCS-based biowaiver requirements as mentioned in Appendix III of Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr - revised 2010).

This application contains a different salt of the active substance. A summary of the literature with regard to non-clinical and clinical data of Sitagliptin Accord and justifications that the different salt of the active substance does not differ significantly in properties with regards to safety and efficacy of the reference product was provided and was accepted by the CHMP. This is in accordance with the relevant guideline and additional non clinical studies were not considered necessary.

The application contains adequate quality data.

A benefit/risk ratio comparable to the reference product can be concluded.

Having considered the data submitted in the application and available on the chosen reference medicinal product, no additional risk minimisation activities are required beyond those included in the product information.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Sitagliptin Accord is favourable in the following indication:

<div style=\"page-break-after: always\"></div>

For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control:

as monotherapy:

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

as dual oral therapy in combination with:

- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
- a peroxisome proliferator-activated receptor gamma (PPAR γ ) agonist (i.e. a thiazolidinedione) when use of a PPAR γ agonist is appropriate and when diet and exercise plus the PPAR γ agonist alone do not provide adequate glycaemic control.

as triple oral therapy in combination with:

- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
- a PPAR γ agonist and metformin when use of a PPAR γ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;

<div style=\"page-break-after: always\"></div>

- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.